title: Multimodality treatment of osteosarcoma: radiation in a high-risk cohort.
abstract: OBJECTIVE
  Chemotherapy during radiation and/or bone-seeking radioisotope therapy (153-samarium; 1 mCi/kg) during radiation may improve osteosarcoma cancer control.
  
  
  METHODS
  We analyzed our preliminary radiation experience in high-risk, metastatic, and/or recurrent patients during a consecutive period of 20 months (May 2005-December 2006).
  
  
  RESULTS
  Thirty-nine high-risk osteosarcoma patients had radiotherapy; 119 sites were irradiated. A median four sites were irradiated per patient (range 1-14). The median radiation dose and number of fractions of radiation was 30 Gy in 10 fractions (range 10-70 Gy in 4-35 fractions). Chemotherapy, most commonly ifosfamide or methotrexate, was used in 80% (100/119) radiotherapy courses. Of 38 painful sites, 29 had improvement (76%), 4 had no change (10%), and 5 had more pain (13%). Objective and potentially durable responses were documented using PET-CT and bone scans with persistent and sustained reduction of standard uptake values (SUVs; initial SUV of indication lesion 9.5 became <4 at all subsequent time points) and serial bone scans [improvement in 29/39 (72%); stable 10/39 (25%), worse 1/39 (3%)]. The actuarial 4-year survival from development of metastasis was 39%.
  
  
  CONCLUSIONS
  Our early results suggest that the use of multimodality therapy including chemotherapy with radiation in unresectable osteosarcoma may be beneficial.
authors.affiliation: Department of Radiation Oncology, UT M.D. Anderson Cancer Center, Houston, Texas, USA. amahajan@mdanderson.org
authors.forename: Anita
authors.initials: A
authors.lastname: Mahajan
authors.forename: Shiao Y
authors.initials: SY
authors.lastname: Woo
authors.forename: David G
authors.initials: DG
authors.lastname: Kornguth
authors.forename: Dennis
authors.initials: D
authors.lastname: Hughes
authors.forename: Winston
authors.initials: W
authors.lastname: Huh
authors.forename: Eric L
authors.initials: EL
authors.lastname: Chang
authors.forename: Cynthia E
authors.initials: CE
authors.lastname: Herzog
authors.forename: Christopher E
authors.initials: CE
authors.lastname: Pelloski
authors.forename: Pete
authors.initials: P
authors.lastname: Anderson
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary / Q000628:therapy*; D002648:Child; D002945:Cisplatin / Q000008:administration & dosage; D015331:Cohort Studies; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008297:Male; D008499:Medical Records; D008727:Methotrexate / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000532:radiotherapy; D012516:Osteosarcoma / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate
chemical_list: D005047:Etoposide; D004317:Doxorubicin; D002945:Cisplatin; D007069:Ifosfamide; D008727:Methotrexate